ProShare Advisors LLC Purchases 12,951 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

ProShare Advisors LLC raised its holdings in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 44.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 41,955 shares of the biopharmaceutical company's stock after acquiring an additional 12,951 shares during the quarter. ProShare Advisors LLC's holdings in TG Therapeutics were worth $1,263,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Quadrant Capital Group LLC raised its holdings in TG Therapeutics by 137.1% during the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock worth $51,000 after purchasing an additional 975 shares during the last quarter. Blue Trust Inc. increased its position in shares of TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 371 shares during the period. Smartleaf Asset Management LLC raised its stake in TG Therapeutics by 512.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after buying an additional 1,594 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in TG Therapeutics by 460.7% in the fourth quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after buying an additional 1,737 shares during the period. Finally, Synergy Asset Management LLC acquired a new position in TG Therapeutics in the fourth quarter valued at $75,000. 58.58% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently weighed in on TGTX shares. Wall Street Zen raised TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a research note on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $40.80.

TG Therapeutics Stock Performance

Shares of TG Therapeutics stock traded up $0.22 during mid-day trading on Wednesday, hitting $35.46. 256,371 shares of the stock were exchanged, compared to its average volume of 2,972,565. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The company has a market capitalization of $5.63 billion, a P/E ratio of -356.11 and a beta of 2.21. The company has a 50-day simple moving average of $37.84 and a 200 day simple moving average of $34.36. TG Therapeutics, Inc. has a 12 month low of $15.16 and a 12 month high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The business had revenue of $120.86 million during the quarter, compared to the consensus estimate of $117.07 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm's revenue for the quarter was up 90.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.07) EPS. Sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.